Guidelines

The Food and Drug Administration has approved a generic of Hoffman-La Roche’s Tamiflu (oseltamivir phosphate) capsules from Lupin. The company’s generic will be available in 30-, 45- and 75-mg dosage strengths.

The product is inficated to treat acute, uncomplicated influenza A and B in patients 2 weeks of age and older, as well as to prevent influenza A and B in patients 1 year old and older. The drug had U.S. sales of roughly $467.8 million for the 12 months ended October 2017, according to IQVIA data.

Amneal Biosciences has launched its generic of Otsuka’s Busulfex (busulfan injection, 6 mg/ml). The product is indicated to treat chronic myelogenous leukemia.

Amneal said that its generic is available in cartons of eight single-dose vials, each of which contains 60 mg of the drug in a 10-ml clear sterile solution. The product is made without natural rubber, latex, gluten or preservatives, Amneal said.

The drug had U.S. sales of roughly $80 million for the 12 months ended October 2017, according to data from IQVIA.
 

It has been announced by Benzer Pharmacy, that the Tampa- Fla.-based chain will be addressing the demand for clinical solutions to supervise overprescribing patients. The company will be tackling this issue by providing medication therapy management, or MTM, to its customers.

“Medication therapy management is a patient-centric approach to bridge the gap between pharmacists and patients. By providing increased access to pharmacists, patients are able to take on a more active role in their wellness journey,” Alpesh Patel, president of Benzer Pharmacy, said.

Pharmacists still are waiting for the handcuffs to come off. That’s the consensus of industry leaders who are frustrated with the challenges of getting reimbursements for a wider range of services these professionals can perform. It’s a topic at the center of enabling patient care in community-based pharmacy.

“We talk about pharmacists being able to practice at the top of their license,” said CVS Health executive vice president of retail pharmacy and supply chain Kevin Hourican.

Lupin has added to its generics lineup with its version of Valeant Pharmaceuticals’ Ancobon (flucytosine) capsules. The drug is indicated to treat serious infections caused by candida and/or Cryptococcus.

The product will be available from Lupin in 250- and 500-mg dosage strengths. These dosage strengths had U.S. sales of roughly $48 million for the 12 months ended October 2017, according to IQVIA data.